Alliance Pharma (Ampersand-backed) Acquires LGC's Drug Development Solutions; KKR Joins as Equal Shareholder

May 17, 2022

Alliance Pharma, an Ampersand-backed US bioanalytical CRO, acquired Drug Development Solutions (DDS), LGC’s UK-based bioanalytical and materials science testing business. Ampersand Capital Partners and KKR will be equal shareholders in the combined business to expand geographic reach, broaden laboratory capabilities, and extend the service portfolio internationally.

Buyers
Alliance Pharma, Ampersand Capital Partners, KKR & Co. Inc.
Targets
Drug Development Solutions (DDS)
Sellers
LGC
Platforms
Alliance Pharma
Location
England, United Kingdom
Transaction Type
Addon

Explore More

Related Acquisitions

Build a buyer list for your deal

Find active buyers from recent acquisition patterns and move straight into outreach.